NASDAQ · HYPD
Healthcare · Medical - Devices
$3.82
Down-$0.07 (-1.80%)
Updated Oct 7, 2026, 3:18 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HYPD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
HYPD closed at $3.82 after 21 trading sessions, up 6.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.94 | $3.99 | $3.76 | $3.82 | 267.71K |
| Oct 5, 2026 | $3.78 | $3.925 | $3.78 | $3.89 | 362.74K |
| Oct 2, 2026 | $3.86 | $3.9498 | $3.705 | $3.73 | 534.4K |
| Oct 1, 2026 | $3.74 | $3.78 | $3.635 | $3.66 | 252.66K |
| Sep 30, 2026 | $4.07 | $4.07 | $3.66 | $3.745 | 853.92K |
| Sep 29, 2026 | $3.96 | $4.00 | $3.78 | $3.99 | 359.53K |
| Sep 28, 2026 | $3.95 | $4.08 | $3.86 | $3.915 | 744.13K |
| Sep 25, 2026 | $4.15 | $4.15 | $3.90 | $4.04 | 584.95K |
| Sep 24, 2026 | $3.74 | $4.17 | $3.73 | $4.17 | 631.39K |
| Sep 23, 2026 | $3.89 | $3.92 | $3.71 | $3.92 | 409.63K |
| Sep 22, 2026 | $3.90 | $4.05 | $3.83 | $3.99 | 548.96K |
| Sep 21, 2026 | $4.12 | $4.145 | $3.83 | $3.85 | 716.98K |
| Sep 18, 2026 | $3.62 | $3.96 | $3.62 | $3.92 | 1.16M |
| Sep 17, 2026 | $3.36 | $3.49 | $3.341 | $3.47 | 337.64K |
| Sep 16, 2026 | $3.30 | $3.315 | $3.18 | $3.27 | 244.14K |
| Sep 15, 2026 | $3.56 | $3.575 | $3.23 | $3.29 | 380.95K |
| Sep 14, 2026 | $3.48 | $3.68 | $3.455 | $3.64 | 509.31K |
| Sep 11, 2026 | $3.77 | $3.88 | $3.47 | $3.49 | 500.38K |
| Sep 10, 2026 | $3.54 | $3.68 | $3.46 | $3.59 | 577.03K |
| Sep 9, 2026 | $3.60 | $3.80 | $3.58 | $3.67 | 545.34K |
| Sep 8, 2026 | $3.32 | $3.67 | $3.17 | $3.58 | 1.47M |
The latest Smart Investors Daily articles mentioning HYPD.
Company
Market Activity
Research & News
HYPD research
Company profile and research snapshot.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or New combinations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 8, 2026 | Chardan Capital | Buy | — |
| Aug 13, 2026 | Chardan Capital | Buy | — |
| Aug 13, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 11, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 9, 2026
Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that it has engaged with the HyperLend protocol ("HyperLend") to create a permissioned lending pool native to the HyperEVM.Through this
Benzinga · Jan 28, 2026
Hyperliquid (CRYPTO: HYPE) is up 65% this week, taking the limelight from bigger and presumably more established tokens, such as XRP
seekingalpha.com · Nov 14, 2025
Hyperion DeFi, Inc. ( HYPD ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Jason Assad Hyunsu Jung - CEO, Chief Investment Officer & Director David Knox - Chief Financial Officer Presentation Operator Greetings, and welcome to Hyperion DeFi's Q3 '25 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
SeekingAlpha · Nov 14, 2025
Hyperion DeFi, Inc. (HYPD) Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsJason AssadHyunsu Jung - CEO, Chief Investment Officer...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HYPD.
